Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients

Autor: Hiroshi Ito, Takashi Kadowaki, Kazuyo Sasaki, Sonoe Hiraide, Masakazu Haneda, Makoto Ueno, Miyuki Matsukawa
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Blood Glucose
Male
medicine.medical_specialty
HbA1c
Eating pattern
Postmarketing surveillance
030209 endocrinology & metabolism
Type 2 diabetes
Dipeptidyl peptidase-4 inhibitor
Teneligliptin
030204 cardiovascular system & hematology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Japan
Internal medicine
medicine
Humans
Hypoglycemic Agents
Pharmacology (medical)
Original Research
Aged
Glycated Hemoglobin
Dipeptidyl-Peptidase IV Inhibitors
business.industry
digestive
oral
and skin physiology
Post-marketing surveillance
General Medicine
Middle Aged
medicine.disease
Interim analysis
Combined Modality Therapy
Hypoglycemia
Postprandial
chemistry
Diabetes Mellitus
Type 2
Hyperglycemia
Pyrazoles
Thiazolidines
Female
Glycated hemoglobin
Diet
Healthy
business
Body mass index
medicine.drug
Zdroj: Advances in Therapy
ISSN: 1865-8652
0741-238X
Popis: Introduction Healthy eating is a critical aspect of the prevention and management of type 2 diabetes (T2DM). Disrupted eating patterns can result in poor glucose control and increase the likelihood of diabetic complications. Teneligliptin inhibits dipeptidyl peptidase-4 activity for 24 h and suppresses postprandial hyperglycemia after all three daily meals. This interim analysis of data from the large-scale post-marketing surveillance of teneligliptin (RUBY) in Japan examined eating patterns and their relationship with metabolic parameters and diabetic complications. We also examined whether eating patterns affected safety and efficacy of teneligliptin. Methods We analyzed baseline data from survey forms collected in RUBY between May 2013 and June 2017, including patient characteristics, metabolic parameters, and eating patterns (eating three meals per day or not; timing of evening meal) before teneligliptin treatment was initiated. Safety and efficacy of 12 months’ teneligliptin (20–40 mg/day) treatment was assessed. Results Data from 10,532 patients were available for analysis. Most patients who did not eat three meals per day (n =757) or who ate their evening meal after 10 PM (n =206) were 64 years old or younger. At baseline, glycated hemoglobin (HbA1c), fasting blood glucose, triglycerides, total and low-density lipoprotein cholesterol, body mass index, alanine aminotransferase, and aspartate aminotransferase levels were higher in those patients who did not eat three meals per day (p
Databáze: OpenAIRE
Externí odkaz: